The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes.
Targeting body weight, as an alternative model to targeting hemoglobin A(1c), is emerging as a viable and potentially cost-effective approach to diabetes management in clinical practice. Why WAIT (Weight Achievement and Intensive Treatment) is a 12-week multidisciplinary program for weight control and intensive diabetes management specifically designed for application in routine diabetes practice. The program, which is generally covered by insurance, is followed by continuous support aimed at long-term maintenance of weight loss and diabetes control. This model was effective in improving key metabolic abnormalities observed in diabetic patients. Eighty-two percent of participants achieved the target hemoglobin A(1c) of less than 7% on less diabetes medications. The achieved weight reduction after 12 weeks of intervention was maintained for an additional year. Future dissemination of this intervention model in routine clinical practice may require wider endorsement by third-party payers and support of governmental health care agencies to halt the progression of the epidemic of obesity and diabetes in the United States.
Hamdy
Osama
O
Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA. Osama.Hamdy@joslin.harvard.edu
Carver
Catherine
C
D001835:Body Weight / Q000502:physiology*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D006442:Glycated Hemoglobin / Q000032:analysis; D006293:Health Promotion / Q000379:methods; D006801:Humans; D008019:Life Style; D008875:Middle Aged; D016896:Treatment Outcome
D006442:Glycated Hemoglobin
Int J Obes (Lond). 2005 Sep;29(9):1115-20
15925953
J Endocrinol Invest. 2005 Dec;28(11):973-7
16483174
Diabetes Care. 2003 Nov;26(11):2977-82
14578226
Int J Obes Relat Metab Disord. 1999 Nov;23(11):1170-7
10578207
Clin Pharmacokinet. 2008;47(1):7-20
18076215
Osteoporos Int. 2005 Dec;16(12):1703-12
15937634
Diabetes Care. 2002 Mar;25(3):425-30
11874925
N Engl J Med. 2002 Feb 7;346(6):393-403
11832527
Am J Prev Med. 1987 Nov-Dec;3(6):339-45
3452374
Diabetes Care. 2003 Jul;26(7):2119-25
12832323
Diabetes Obes Metab. 2004 Mar;6(2):85-94
14746573
Obes Res. 2002 Dec;10 Suppl 2:124S-130S
12490661
Curr Diab Rep. 2006 Nov;6(5):405-8
17139804
Diabetes Care. 1993 Jan;16(1):21-31
8422777
Curr Med Res Opin. 2007 Sep;23(9):2157-69
17669232
Diabetes Self Manag. 2005 Nov-Dec;22(6):40, 42-4
16355469
JAMA. 2002 Oct 9;288(14):1723-7
12365955
JAMA. 1999 Jun 2;281(21):2005-12
10359389
Gut. 2004 Mar;53(3):413-9
14960526
Diabetologia. 2004 Oct;47(10):1677-86
15480538
Diabetes Care. 2007 Jun;30(6):1374-83
17363746
Metabolism. 2004 Mar;53(3):284-9
15015138
Ethn Dis. 2007 Winter;17(1):35-9
17274207
Int J Clin Pract. 2008 Apr;62(4):659-65
18324957
J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S213-7
17130264
Diabetologia. 2008 Mar;51(3):408-16
18204830
Obes Surg. 2006 Oct;16(10):1278-86
17059735
Nutr Metab (Lond). 2006 Mar 23;3:16
16556307
Diabetes Care. 1998 Sep;21(9):1414-31
9727886
Obes Res. 2003 Sep;11(9):1048-54
12972674